- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of bilastine.
Seasonal and perennial allergic rhino-conjunctivitis
Treatment should be taken one hour before or two hours after food or fruit juice.
20mg once daily.
Children over 12 years
20mg once daily
Orodispersible tablet and oral solution
Children aged 6 to 12 years weighing at least 20kg
10mg orodispersible tablet once daily or 4ml of 2.5mg/ml oral solution once daily
Children aged under 6 years and weighing less than 20kg
Patients with Renal Impairment
In patients with moderate or severe renal impairment, co-administration of bilastine with P-glycoprotein inhibitors, such as ketoconazole, erythromycin, cyclosporine, ritonavir or diltiazem, may increase plasmatic levels of bilastine and, therefore, increase the risk of adverse effects of bilastine.
Additional Dosage Information
Allergic rhinitis: Limit the treatment to the period of allergens exposure.
Seasonal allergic rhinitis: Discontinue treatment after symptoms have resolved and reinitiate when symptoms return.
Perennial allergic rhinitis: Treatment may continue during the allergen exposure periods.
Urticaria: Duration of treatment depends on the type, duration and symptoms.
Children under 6 years
Children weighing less than 20kg
Precautions and Warnings
Children 6 to 12 years
Advise patient not to drive until they know how the medicine affects them
Not all formulations are suitable for use in children under 12 years
Oral liquid contains hydroxybenzoate: caution in hypersensitivity
Grapefruit juice should not be taken simultaneously
Pregnancy and Lactation
Use bilastine with caution in pregnancy.
The manufacturer does not recommend using bilastine during pregnancy. At the time of writing animal studies have not indicated any direct or indirect harmful effects with respect to reproductive toxicity, parturition or postnatal development.
Use bilastine with caution in breastfeeding.
The manufacturer advises that the patient either discontinues bilastine treatment or discontinues breastfeeding, taking into account the benefit of breastfeeding to the child and the benefit of bilastine therapy to the mother. Animal data reports have shown excretion of bilastine in breast milk however presence in human breast milk is unknown.
Alanine aminotransferase increased
Aspartate aminotransferase increased
Elevated triglyceride levels
Gamma glutamyl transferase (GGT) increased
Increase in creatinine
Loss of consciousness (transient)
Oedema of the lips
Prolongation of QT interval
Right bundle branch block
Upper abdominal pain
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2020
Summary of Product Characteristics: Ilaxten 20mg tablets. Menarini International Operations Luxembourg S.A. Revised August 2019.
Summary of Product Characteristics: Ilaxten 10mg orodispersible tablets. Menarini International Operations Luxembourg S.A. Revised February 2019.
Summary of Product Characteristics: Ilaxten 2.5mg/ml oral solution. Menarini International Operations Luxembourg S.A. Revised February 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.